June 17, 2016.
Bristol-Myers Squibb (BMS) reports that the National Institute for Health and Care Excellence (NICE)’s recommendation of the combination therapy of Opdivo to treat UK NHS patients with advanced skin cancer is one of the fastest approvals from NICE to date, issued just weeks after the combination was licensed by the European Commission on May 11 this year.
BMS states that the NICE decision was supported by data from a Phase III clinical study, in which some patients treated with the combination therapy saw their cancer kept at bay for almost four times longer than those treated with ipilimumab alone, regardless of BRAF gene mutational status.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.